{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:18:23Z","timestamp":1763018303581,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00277-020-04355-1","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T23:07:02Z","timestamp":1606259222000},"page":"1579-1591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8146","authenticated-orcid":false,"given":"Yue","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao-Pei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"4355_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. Version 3. 2020. (Guidelines)"},{"issue":"7","key":"4355_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1182\/bloodadvances.2016002386","volume":"1","author":"J Versluis","year":"2017","unstructured":"Versluis J, Labopin M, Ruggeri A, Socie G et al (2017) Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv 1(7):477\u2013485","journal-title":"Blood Adv"},{"key":"4355_CR3","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1007\/s00277-019-03771-2","volume":"98","author":"S Giebel","year":"2019","unstructured":"Giebel S, Boumendil A, Labopin M (2019) Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Ann Hematol 98:2389\u20132398","journal-title":"Ann Hematol"},{"key":"4355_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/bmt.2016.217","volume":"51","author":"A Rashidi","year":"2016","unstructured":"Rashidi A, Slade M, DiPersio JF, Westervelt P et al (2016) Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. Bone Marrow Transplant 51:1561\u20131564","journal-title":"Bone Marrow Transplant"},{"key":"4355_CR5","doi-asserted-by":"publisher","first-page":"125e133","DOI":"10.1016\/j.bbmt.2015.09.002","volume":"22","author":"A Bashey","year":"2016","unstructured":"Bashey A, Xu Z, Jackson K et al (2016) Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant 22:125e133","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"4355_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127(20):2391\u20132405","journal-title":"Blood."},{"issue":"6","key":"4355_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","volume":"124","author":"W Yu","year":"2014","unstructured":"Yu W, Chang Y-J, Xu L-P et al (2014) Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 124(6):843\u2013850","journal-title":"Blood."},{"issue":"13","key":"4355_CR8","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","volume":"96","author":"ML Slovak","year":"2000","unstructured":"Slovak ML, Kopecky KJ, Peter A. Cassileth, et al. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study. Blood. 96(13):4075\u20134083","journal-title":"Blood."},{"issue":"4","key":"4355_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an International Expert Panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"8","key":"4355_CR10","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 106(8):2912\u20132919","journal-title":"Blood."},{"key":"4355_CR11","doi-asserted-by":"crossref","unstructured":"Stefan O Ciurea , Kai Cao, Marcelo Fernandez-Vina, Piyanuch Kongtim, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant2018;53(5):521-534.","DOI":"10.1038\/s41409-017-0062-8"},{"issue":"8","key":"4355_CR12","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","volume":"107","author":"D-P Lu","year":"2006","unstructured":"Lu D-P, Dong L, Wu T, Huang X-J et al (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 107(8):3065\u20133073","journal-title":"Blood."},{"key":"4355_CR13","doi-asserted-by":"publisher","first-page":"4e10","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S et al (2016) International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 22:4e10","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4355_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Hildegard T, Greinix MA et al (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 21(3):389\u2013401","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"4355_CR15","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.bbmt.2014.08.013","volume":"20","author":"A Di Stasi","year":"2014","unstructured":"Di Stasi A, Milton DR, Poon LM et al (2014) Similar transplant outcomes for AML\/MDS patients with haploidentical versus 10\/10 HLA matched unrelated and related donors. Biol Blood Marrow Transplant 20(12):1975\u20131981","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"4355_CR16","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"W Yu","year":"2015","unstructured":"Yu W, Liu Q-F, Xu L-P, Liu K-Y et al (2015) Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125(25):3956\u20133962","journal-title":"Blood"},{"issue":"8","key":"4355_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"D Salvatore","year":"2018","unstructured":"Salvatore D, Labopin M, Ruggeri A et al (2018) Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 103(8):1317\u20131328","journal-title":"Haematologica"},{"issue":"2","key":"4355_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/leu.2015.232","volume":"30","author":"O Ringd\u00e9n","year":"2016","unstructured":"Ringd\u00e9n O, Labopin M, Ciceri F, Velardi A et al (2016) Is there a stronger graft-versus-leukemia effect using HLA haploidentical donors than with HLA-identical siblings? Leukemia. 30(2):447\u2013455","journal-title":"Leukemia."},{"issue":"1","key":"4355_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"Y-J Chang","year":"2017","unstructured":"Chang Y-J, Yu W, Liu Y-R, Xu L-P et al (2017) Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol 10(1):134","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4355_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bbmt.2010.08.023","volume":"17","author":"W Yu","year":"2011","unstructured":"Yu W, Liu D-H, Xu L-P, Liu K-Y et al (2011 Jun) Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 17(6):821\u2013830","journal-title":"Biol Blood Marrow Transplant"},{"key":"4355_CR21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","volume":"23","author":"BM Getta","year":"2017","unstructured":"Getta BM, Devlin SM, Levine RL et al (2017) Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol Blood Marrow Transplant 23:1064\u20131071","journal-title":"Biol Blood Marrow Transplant"},{"key":"4355_CR22","doi-asserted-by":"publisher","first-page":"9495","DOI":"10.2147\/CMAR.S225123","volume":"11","author":"S Feng","year":"2019","unstructured":"Feng S, Zhou L, Zhang X, Tang B, Zhu X et al (2019) Impact of ELN risk stratification, induction chemotherapy regimens and hematopoietic stem cell transplantation on outcomes in hyperleukocytic acute myeloid leukemia with initial white blood cell count more than 100 \u00d7 109\/L. Cancer Manag Res 11:9495\u20139503","journal-title":"Cancer Manag Res"},{"issue":"3","key":"4355_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-020-0296-3","volume":"10","author":"A-K Schmaelter","year":"2020","unstructured":"Schmaelter A-K, Labopin M, Soci\u00e9 G, It\u00e4l\u00e4-Remes M et al (2020) Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J 10(3):26","journal-title":"Blood Cancer J"},{"issue":"19","key":"4355_CR24","doi-asserted-by":"publisher","first-page":"e15584","DOI":"10.1097\/MD.0000000000015584","volume":"98","author":"MD Ning Xie","year":"2019","unstructured":"Ning Xie MD, Jian Zhou PD, Yanli Zhang MD et al (2019 May) Extramedullary relapse of leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective study. Medicine (Baltimore) 98(19):e15584","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"4355_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41409-019-0461-0","volume":"54","author":"Y Okamoto","year":"2019","unstructured":"Okamoto Y, Kudo K, Tabuchi K, Tomizawa D et al (2019 Sep) Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. Bone Marrow Transplant 54(9):1489\u20131498","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"4355_CR26","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter RB, Buckley SA, John M. Pagel, et al. (2013) Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 122(10):1813\u20131821","journal-title":"Blood."},{"issue":"9","key":"4355_CR27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Gooley TA, Wood BL, Milano F et al (2011) Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29(9):1190\u20131197","journal-title":"J Clin Oncol"},{"key":"4355_CR28","doi-asserted-by":"publisher","first-page":"1573e1579","DOI":"10.1016\/j.bbmt.2014.05.029","volume":"20","author":"AM Raiola","year":"2014","unstructured":"Raiola AM, Dominietto A, di Grazia C et al (2014) Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 20:1573e1579","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"4355_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/146532400539369","volume":"2","author":"G Miflin","year":"2000","unstructured":"Miflin G, Russell NH, Franklin I, Cook G, Milligan DW et al (2000) An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. Cytotherapy. 2(6):423\u2013428","journal-title":"Cytotherapy."}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04355-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04355-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T06:14:40Z","timestamp":1620800080000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04355-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["4355"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04355-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}